Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Liabilities from Discontinued Operations (2022 - 2023)

Senti Biosciences has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 243000.0 for Q4 2023.

  • For Q4 2023, Liabilities from Discontinued Operations fell 79.49% year-over-year to 243000.0; the TTM value through Dec 2023 reached 243000.0, down 79.49%, while the annual FY2023 figure was 243000.0, 79.49% down from the prior year.
  • Liabilities from Discontinued Operations for Q4 2023 was 243000.0 at Senti Biosciences, up from 216000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 1185000.0 in Q4 2022 and troughed at 216000.0 in Q3 2023.